The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.

Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.

Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results (January 2025) showed a 62% gastrointestinal overall response rate at Day 28 and 1-year ...